CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|December 29, 2021
Best Read Articles on Formularies and Formulary Changes in 2021
Author(s)Briana Contreras
Our best read stories about formularies include news about 2022 formularies from CVS Caremark and Express Scripts.
Advertisement
Express Scripts Releases List of 2022 Formulary Exclusions
Four products on the preferred list this year will be excluded next year.
Non-opioid Pain Therapeutic Achieves More Than 100 Formulary Approvals
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
CVS Caremark Announces Formulary for 2022
CVS Caremark has removed 10 branded products from its formulary and added about 30 additional products.
Cigna Releases Formulary Changes for 2022
Cigna plans to remove 45 drugs from its Standard Prescription Drug List and add restrictions for other therapeutics.
Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
2
Why consumers still can’t comparison shop for medication
3
When the referral isn't the finish line: Making SDOH programs actually close care gaps
4
The hidden costs of routine radiology and how they can be addressed
5